Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ferriby, D.
Right arrow Articles by Vermersch, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferriby, D.
Right arrow Articles by Vermersch, P.
Neurology 2001;57:927-929
© 2001 American Academy of Neurology


Brief Communications

Long-term follow-up of neurosarcoidosis

D. Ferriby, MD;, J. de Seze, MD;, T. Stojkovic, MD;, E. Hachulla, MD;, B. Wallaert, MD;, A. Destée, MD;, P. Y. Hatron, MD; and P. Vermersch, MD

From the Departments of Neurology (Drs. Ferriby, de Seze, Stojkovic, Destée, and Vermersch), Internal Medicine (Drs. Hachulla and Hatron), and Pneumology (Dr. Wallaert), CHRU de Lille, France.

Address correspondence and reprint requests to Dr. D. Ferriby, Clinique Neurologique, Service de Neurologie D, Hôpital Roger Salengro, CHRU Lille, 59037 Lille Cedex; e-mail: d-ferriby{at}chru-lille.fr

The authors evaluated the long-term clinical outcome of neurosarcoidosis and determined predictive factors of disease course. Twenty-seven patients with neurosarcoidosis were followed for at least 5 years from the onset of neurologic symptoms. Patients with CNS involvement during the course of the disease had a higher Modified Oxford Handicap Scale score than those with peripheral nervous system involvement (p < 0.02). CNS involvement may be a predictive factor for a less favorable disease course. Early and intensive treatment should be considered in such cases.




This article has been cited by other articles:


Home page
NeurologyHome page
M. Moravan and B. M. Segal
Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil
Neurology, January 27, 2009; 72(4): 337 - 340.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
T. F. Scott, K. Yandora, A. Valeri, C. Chieffe, and C. Schramke
Aggressive Therapy for Neurosarcoidosis: Long-term Follow-up of 48 Treated Patients
Arch Neurol, May 1, 2007; 64(5): 691 - 696.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
R. J. Baumann and W. C. Robertson Jr
Neurosarcoid Presents Differently in Children Than in Adults
Pediatrics, December 1, 2003; 112(6): e480 - 486.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by AAN Enterprises, Inc.